Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
Minke He(Sun Yat-sen University), Ming Shi(Yanshan University), Yaojun Zhang(Sun Yat-sen University), Yuan-Min Zhou(Twelfth Guangzhou City People's Hospital), ZhiCheng Lai(Sun Yat-sen University), Li Xu(Jiangxi University of Traditional Chinese Medicine), Wei Wei(Zhujiang Hospital), Yang Zhao, Yu-Jie Xu(Guangzhou First People's Hospital), Minshan Chen(Sun Yat-sen University), Huanwei Chen(Changhua Christian Hospital), QiJiong Li(Sun Yat-sen University), Run-Bin Liang(Sun Yat-sen University), Rong Guo(Sun Yat-sen University)
Cited by 216
Related Papers
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576